Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus kefiranofaciens
- Development stage
- Preclinical
- Lead developer
- Daiwa Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus kefiranofaciens* is a non-pathogenic, gram-positive probiotic bacterium primarily isolated from kefir grains. It is a live biotherapeutic product (LBP) characterized by its ability to produce kefiran, an extracellular branched water-soluble polysaccharide composed of glucose and galactose. Research, including work by Daiwa Pharmaceutical, indicates that *L. kefiranofaciens* can reprogram the gut microenvironment, repair the intestinal barrier, and provide antioxidant defense against reactive oxygen species (ROS). It is being investigated for potential therapeutic applications in ulcerative colitis, sepsis, inflammatory bowel disease (IBD), metabolic disorders, and depression-related symptoms. Various strains, such as M1, KCTC 5075, and ATCC 43761, have been studied for their immunomodulatory and anti-inflammatory bioactivities. Recent research has also explored advanced delivery systems, such as prebiotic-augmented nanozyme-armoring, to enhance its efficacy in treating colitis and sepsis.
- Other names
- L. kefiranofaciens
Beyond the preview
Go deeper on Lactobacillus kefiranofaciens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus kefiranofaciens.